<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0122-0667</journal-id>
<journal-title><![CDATA[Revista Médica de Risaralda]]></journal-title>
<abbrev-journal-title><![CDATA[Revista médica Risaralda]]></abbrev-journal-title>
<issn>0122-0667</issn>
<publisher>
<publisher-name><![CDATA[Universidad Tecnológica de Pereira]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0122-06672020000200097</article-id>
<article-id pub-id-type="doi">10.22517/25395203.24533</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores demográficos y clínicos que explican la progresión de la Enfermedad Renal Crónica en un programa de nefroprotección del departamento de Nariño, Colombia 2016-2018]]></article-title>
<article-title xml:lang="en"><![CDATA[Demographic and clinical factors that explain the progression of Chronic Kidney Disease in a nephroprotection program in the department of Nariño, Colombia between 2016-2018.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bastidas]]></surname>
<given-names><![CDATA[Bertha Ligia Bernal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quirós Gómez]]></surname>
<given-names><![CDATA[Oscar Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,aff1  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,aff2  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad CES Medellín  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>26</volume>
<numero>2</numero>
<fpage>97</fpage>
<lpage>109</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0122-06672020000200097&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0122-06672020000200097&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0122-06672020000200097&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La Enfermedad Renal Crónica es una patología de gran impacto en salud pública a nivel mundial, su progresión está determinada por limitaciones en el control de sus factores de riesgo y pronóstico. Los programas de nefroprotección hacen seguimiento y control de los pacientes con la enfermedad, intentando llevarlos a cumplir las metas específicas de nefroprotección para limitar la progresión de la Enfermedad Renal Crónica.  Objetivo:  Determinar los factores explicativos de la progresión de la Enfermedad Renal Crónica en pacientes atendidos en un programa de nefroprotección.  Materiales y métodos:  Estudio analítico observacional de cohorte retrospectivo en 5872 pacientes con Enfermedad Renal Crónica en diferentes estadios, participantes de un programa de nefroprotección en el departamento de Nariño durante el período 2016-2018. La progresión de la ERC, correspondió a la disminución de la Tasa de Filtración Glomerular en 5mL/min/1.73 m2 o más. La información se obtuvo de la base de datos del programa. Se construyó un modelo explicativo ajustado por variables demográficas y clínicas. Acorde al diseño se utilizó un modelo binomial con función de enlace logarítmica para estimar los coeficientes de regresión de las variables de interés. Las medidas de asociación fueron los Riesgos Relativos.  Resultados: el 72,2% fueron mujeres, el 75,1% tenían 60 años o más, el 12,4% eran afrocolombinos, y el 85% mestizos, se presentó progresión el 49,2% (IC 95% 47,9-50,4) de los casos. Los factores que mejor explicaron la relación la progresión de ERC, fueron: ser hombre con un RR ajustado de 1,04 (IC95%:1,00-1,15), y tener un estadio de la ERC, de 4, 5 y 3a-b, con RR ajustado 1,62 (IC1,36-1,94) y 1,41 (IC1,21-1,63) respectivamente.  Conclusiones:  En la población nariñense de Colombia afiliada a un programa de nefroprotección, la progresión de la ERC fue del 49,2%, siendo explicada de forma significativa por el sexo masculino, y los estadios avanzados de la enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Chronic Kidney Disease is a pathology of great impact on public health worldwide, its progression is determined by limitations in the control of its risk factors and prognosis. Nephroprotection programs monitor, control, and limit the progression of this disease in the patients while trying to lead them to meet the specific program goals.  Objective:  To determine the factors that boost the progression of Chronic Kidney Disease in patients treated in a nephroprotection program.  Materials and methods:  This retrospective analytical observational cohort study was carried out in 5872 patients from a nephroprotection program with different stages of Chronic Kidney Disease, in the department of Nariño between 2016 and 2018. The progression of CKD corresponded to a decrease in the Glomerular Filtration Rate by 5mL / min / 1.73 m2 or more; this information was obtained from the program's database. An explanatory model was built and adjusted taking into consideration demographic and clinical variables. According to the design, a binomial model with a logarithmic link function was used to estimate the regression coefficients of the variables of interest. The association measures were the Relative risks.  Results:  In the final results it was found that 72.2% were women, 75.1% were 60 years old or older, 12.4% were afro-colombian, 85% were mixed race, and 49.2% presented progression (95% CI 47 , 9-50.4) of the cases. The factors that best explained the relationship between CKD progression were: being a man with an adjusted RR of 1.04 (95% CI: 1.00-1.15), and having a CKD stage of 4, 5 and 3a-b, with adjusted RR 1.62 (CI1.36-1.94) and 1.41 (CI1.21-1.63) respectively.  Conclusions:  In the Nariño population of Colombia that is affiliated to a nephroprotection program the progression of CKD was 49.2% according to the male sex and the advanced stages of the condition.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Progresión de la enfermedad]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo2]]></kwd>
<kwd lng="es"><![CDATA[hipertensión]]></kwd>
<kwd lng="es"><![CDATA[insuficiencia renal crónica]]></kwd>
<kwd lng="en"><![CDATA[disease progression]]></kwd>
<kwd lng="en"><![CDATA[type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[hypertension]]></kwd>
<kwd lng="en"><![CDATA[chronic kidney failure]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eknoyan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lameire]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Eckardt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>5-14</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[J-C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L-X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and Disease Burden of Chronic Kidney Disease]]></article-title>
<source><![CDATA[Renal Fibrosis: Mechanisms and Therapies]]></source>
<year>2019</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-15</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jha]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Garcia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Iseki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Naicker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Plattner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic kidney disease: global dimension and perspectives]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9888</numero>
<issue>9888</issue>
<page-range>260-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acuña]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Valbuena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Situación de la Enfermedad Renal Crónica, la hipertensión arterial y la diabetes mellitus en Colombia 2019. Cuenta de Alto Costo]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Bogotá D.C ]]></publisher-loc>
<publisher-name><![CDATA[Fondo Colombiano de Enfermedades de Alto Costo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Francisco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gayoso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[on behalf of the EPIRCE. Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2010</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>78-86</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Górriz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de consenso para la detección y manejo de la enfermedad renal crónica]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2014</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>243-62</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sellares]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad renal crónica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Goez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrología al día]]></source>
<year>2010</year>
<page-range>335-52</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Edición del grupo editorial nefrología de la sociedad española de nefrología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acuña]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad renal crónica en Colombia: prioridad para la gestión de riesgo]]></article-title>
<source><![CDATA[Rev. Panam. Salud Pública]]></source>
<year>2016</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halbesma]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Brantsma]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Bakker]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gender differences in predictors of the decline of renal function in the general population]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Coordinación metodológica de la Cuenta de Alto Costo</collab>
<source><![CDATA[Contenidos mínimos indispensables para la gestión del riesgo renal en un programa de atención a pacientes adultos con enfermedad renal crónica, sin terapia de reemplazo renal en Colombia. Definiciones técnicas basadas en evidencia]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>Fondo Colombiano de Enfermedades de Alto Costo</collab>
<source><![CDATA[Nefroprotección: Estrategia fundamental para evitar, controlar y retrasar el daño renal. Boletín de Información Técnica especializada]]></source>
<year>2016</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores asociados a Enfermedad renal crónica en estadios pre diálisis]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Medellín, Antioquia ]]></publisher-loc>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertakis]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Azari]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Helms]]></surname>
<given-names><![CDATA[LJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gender differences in the utilization of health care services]]></article-title>
<source><![CDATA[J Fam Pract]]></source>
<year>2000</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>147-52</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bardají]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Vea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad renal crónica y corazón. Un continuo evolutivo]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2008</year>
<volume>61</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>41-51</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vikse]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Irgens]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Leivestad]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low birth weight increases risk for endstage renal disease]]></article-title>
<source><![CDATA[Journal of the American Society of Nephrology: JASN]]></source>
<year>2008</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>151-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chavez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Galvez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progresión de la Enfermedad renal crónica en un hospital de referencia de la seguridad social de Perú 2012-2015]]></article-title>
<source><![CDATA[Rev Perú Med Exp Salud Publica]]></source>
<year>2017</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>209-17</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zúñiga SM]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Müller O]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Flores O]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de enfermedad renal crónica en centros urbanos de atención primaria]]></article-title>
<source><![CDATA[Rev Médica Chile]]></source>
<year>2011</year>
<volume>139</volume>
<page-range>1176-84</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Castelao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Górriz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Bover]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Segura-de la Morena]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cebollada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Escalada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus document for the detection and management of chronic kidney disease]]></article-title>
<source><![CDATA[Endocrinol Nutr Órgano Soc Esp Endocrinol Nutr]]></source>
<year>2014</year>
<volume>61</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>e25-43</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[Andong]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[Chunlei]]></given-names>
</name>
<name>
<surname><![CDATA[Hongxia]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and Associated Risk Factors of Chronic Kidney Disease in an Elderly Population from Eastern China]]></article-title>
<source><![CDATA[International Journal of Environmental Research and Public Health]]></source>
<year>2019</year>
<volume>16</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>4383</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores asociados a Enfermedad renal crónica en estadios pre diálisis]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Medellín, Antioquia ]]></publisher-loc>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[DAchiadi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo para la progresión de la enfermedad renal crónica en pacientes con nefropatía diabética estadios 3-4 del Servicio de Nefrología del Hospital Militar Central de Bogotá]]></article-title>
<source><![CDATA[Rev. Nefrología]]></source>
<year>2014</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Applying the new intensive blood pressure categories to a nondialysis chronic kidney disease population: the Prevalence, Awareness and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China survey.]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2020</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>155-61</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vikse]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Irgens]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Leivestad]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low birth weight increases risk for endstage renal disease]]></article-title>
<source><![CDATA[Journal of the American Society of Nephrology: JASN]]></source>
<year>2008</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>151-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal replacement therapy in the Canary Islands: demographic and survival analysis]]></article-title>
<source><![CDATA[J Nephrol]]></source>
<year>2006</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-103</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Saracho]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rufino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Similar renal decline in diabetic and nondiabetic patients with comparable levels of albuminuria]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2010</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>835-41</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Kuperman]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Curhan]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2000</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>272-81</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<collab>European Dialysis and Transplant Association</collab>
<article-title xml:lang=""><![CDATA[Guideline development: Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher]]></article-title>
<collab>European Renal Association</collab>
<source><![CDATA[Nephrology, dialysis, transplantation]]></source>
<year>2015</year>
<volume>30</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>1-142</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez-Huelgas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez- Castelao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2013</year>
<volume>1</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>0-138</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dearbhla]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Rothwell]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disentangling the multiple links between renal dysfunction and cerebrovascular disease.]]></article-title>
<source><![CDATA[Neurol Neurosurg Psychiatry]]></source>
<year>2020</year>
<volume>91</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>88-97</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorostidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de la Sierra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Albarran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes]]></article-title>
<source><![CDATA[Hypertens. Res]]></source>
<year>2011</year>
<volume>34</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1185-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Luke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bidani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2005</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>587-94</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Provenzano]]></surname>
</name>
<name>
<surname><![CDATA[Chiodini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Minutolo]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics]]></article-title>
<source><![CDATA[Nephrol. Dial Transplant]]></source>
<year>2020</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>138-47</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
